DSIP

Overview

Delta Sleep Inducing Peptide (DSIP) is a nine-amino-acid neuropeptide first isolated in 1977 by Schoenenberger and Monnier from the cerebral venous blood of rabbits during electrically induced sleep. The peptide was named for its ability to promote delta wave (slow-wave) sleep in recipient rabbits when administered intravenously — a finding that generated substantial interest in the neuroscience of sleep regulation.

DSIP is found endogenously in the brain, pituitary gland, and peripheral organs of various mammals including humans. It circulates in plasma both in free form and bound to a carrier protein, with concentrations showing diurnal variation. Despite nearly five decades of research, DSIP's precise receptor target and complete signaling mechanism remain incompletely characterized — an unusual situation for a peptide with such a long research history.

The peptide has been studied across a broad range of physiological contexts beyond sleep, including stress response, pain modulation, endocrine regulation, and oxidative stress protection. Limited clinical studies were conducted in Europe during the 1980s and 1990s, particularly in Germany and Switzerland, examining DSIP in insomnia, chronic pain, narcolepsy, alcohol and opioid withdrawal, and depression. While DSIP has never received regulatory approval for any clinical indication, it remains a subject of ongoing research interest.

Structure and Sequence

Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE)

• Molecular formula: C₃₅H₄₈N₁₀O₁₅
• Molecular weight: 848.81 g/mol
• CAS Number: 62568-57-4
• Isoelectric point: Approximately 3.5 (acidic peptide)
• Phosphorylated form: DSIP exists in both non-phosphorylated and phosphorylated forms (phosphoserine at position 7), which may differ in biological activity

The peptide is notable for its lack of basic amino acid residues, giving it an overall acidic character. The phosphorylation of Ser-7 is considered physiologically relevant, with some researchers suggesting the phosphorylated form (pDSIP) may represent the primary circulating species with distinct receptor interactions.

Mechanism of Action

Sleep Regulation

DSIP's somnogenic (sleep-promoting) effects appear to involve multiple pathways:

• GABAergic modulation — DSIP has been shown to enhance GABAergic transmission, the primary inhibitory neurotransmitter system involved in sleep initiation and maintenance
• Serotonin system interaction — Modulation of serotonergic activity in sleep-regulatory brain regions
• Circadian oscillator influence — DSIP may interact with circadian clock mechanisms, with evidence suggesting effects on the timing and sleep architecture rather than simple sedation
• Glutamate modulation — Reported interactions with glutamate release and NMDA receptor function

Importantly, DSIP does not appear to induce sleep by a simple sedative mechanism. Rather, studies suggest it normalizes disturbed sleep patterns and promotes the natural transition into slow-wave (delta) sleep, particularly in individuals with pre-existing sleep disruption.

Stress and HPA Axis Modulation

DSIP has demonstrated stress-protective properties in multiple experimental paradigms:

• Modulation of the hypothalamic-pituitary-adrenal (HPA) axis stress response
• Reduction of stress-induced corticotropin-releasing hormone (CRH) release
• Attenuation of ACTH and cortisol responses to acute stressors in animal models
• Potential involvement in the adaptive stress response, with repeated DSIP administration showing stress-resilience effects

Opioid System Interactions

DSIP interacts with the endogenous opioid system, though it does not bind directly to classical opioid receptors:

• Modulation of met-enkephalin and beta-endorphin levels
• Potential involvement in endogenous pain modulation systems
• Interactions with opioid tolerance and withdrawal mechanisms, leading to investigation in addiction research

Antioxidant and Cytoprotective Effects

Research has demonstrated DSIP's ability to:

• Reduce lipid peroxidation in brain tissue
• Enhance the activity of endogenous antioxidant enzymes (superoxide dismutase, catalase)
• Protect against oxidative stress-induced cellular damage
• Exhibit geroprotective (anti-aging) properties in animal models of accelerated aging

Endocrine Modulation

DSIP influences several endocrine systems:

• Modulation of growth hormone release patterns
• Effects on luteinizing hormone (LH) secretion
• Influence on thyroid-stimulating hormone (TSH) release
• Interaction with somatostatin signaling

Research Summary

Area of Study	Key Finding	Notable Reference
Original isolation	Isolated from rabbit brain venous blood during electrically induced sleep; promoted delta sleep in recipients	Schoenenberger & Monnier, PNAS, 1977
Insomnia (human)	Improved sleep onset and quality in chronic insomnia patients (n=16); normalized sleep architecture	Schneider-Helmert & Schoenenberger, European Neurology, 1986
Chronic pain (human)	Reduced pain perception in chronic pain patients; improved associated sleep disturbances	Larbig et al., European Journal of Pharmacology, 1984
Narcolepsy (human)	Improved daytime alertness and reduced sleep attacks in narcolepsy patients	Schneider-Helmert, European Neurology, 1984
Alcohol withdrawal	Ameliorated alcohol withdrawal symptoms in clinical studies; reduced anxiety and sleep disruption	Dick et al., Neuropsychobiology, 1984
Opioid withdrawal	Attenuated opiate withdrawal symptoms in limited human studies	Iyer et al., Pharmacology Biochemistry and Behavior, 1988
Stress protection	Protected against stress-induced functional disturbances in rats; reduced corticosterone elevations	Sudakov et al., Regulatory Peptides, 1995
Antioxidant activity	Reduced lipid peroxidation and enhanced antioxidant enzyme activity in brain tissue	Khvatova et al., Peptides, 2003
Geroprotection	Extended lifespan in Drosophila models; reduced age-related biomarker deterioration	Khavinson & Anisimov, Biogerontology, 2000
Endocrine effects	Modulated GH and LH secretion patterns in both animal and human studies	Graf & Kastin, Peptides, 1986
Depression (human)	Improved depressive symptoms in a small clinical series when combined with sleep deprivation therapy	Schneider-Helmert, International Journal of Clinical Pharmacology, 1985

Pharmacokinetics

• Half-life: Approximately 7-8 minutes in plasma in free form. However, DSIP circulates bound to a carrier protein that may extend its effective duration
• Blood-brain barrier: Crosses the blood-brain barrier via a non-saturable mechanism, likely transcytosis
• Plasma forms: Present in both free (approximately 15%) and protein-bound (approximately 85%) forms
• Diurnal variation: Endogenous plasma concentrations show circadian variation, with levels reported to differ between day and night
• Metabolism: Rapidly degraded by aminopeptidases; the N-terminal tryptophan is a primary cleavage site
• Stability considerations: The lyophilized form is relatively stable, but reconstituted solutions degrade rapidly and require refrigeration

The short plasma half-life of free DSIP has been a significant challenge for therapeutic development. Analogs with improved stability (including D-amino acid substitutions at the N-terminus) have been investigated to address this limitation.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for DSIP. Always consult a qualified healthcare professional.

Standard Subcutaneous Protocol

Schedule	Dose	Timing	Duration
5 days on / 2 days off	100–300 mcg	Before bed	4-week cycles

Reconstitution (5 mg vial)

• Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration
• At this concentration: 1 unit = 25 mcg on a U-100 insulin syringe
• 100 mcg = 4 units | 200 mcg = 8 units | 300 mcg = 12 units

Key Points

• Route: Subcutaneous injection
• Injection timing: 30–60 minutes before bed
• Cycle length: 4 weeks on, 2–4 weeks off
• Schedule: 5 days on, 2 days off to prevent tolerance
• Storage note: Reconstituted DSIP degrades faster than most peptides — use within 2 weeks and keep refrigerated
• Mechanism: DSIP promotes delta (slow-wave) sleep architecture rather than acting as a sedative

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Parameter	Value
Vial size	5 mg
Bacteriostatic water	3.0 mL
Concentration	~1,667 mcg/mL
Storage (reconstituted)	2-8 °C, use within 2 weeks
Storage (lyophilized)	-20 °C

Dosing Schedule

Phase	Dose	Frequency	Duration
Starting	100 mcg	Once daily, before bedtime	Weeks 1-2
Mid-range	150-200 mcg	Once daily, before bedtime	Weeks 3-4
Target	250-300 mcg	Once daily, before bedtime	Weeks 5-8

Syringe Measurements (U-100 insulin syringe)

Dose	Units	Volume
100 mcg	6 units	0.06 mL
150 mcg	9 units	0.09 mL
200 mcg	12 units	0.12 mL
300 mcg	18 units	0.18 mL

Cycle Guidelines

• Cycle length: 4-8 weeks (up to 12 weeks with periodic breaks)
• Route: Subcutaneous injection
• Timing: Evening/bedtime administration (DSIP promotes delta slow-wave sleep)
• Titration: Increase by ~50 mcg every 1-2 weeks
• Injection sites: Rotate between abdomen, thighs, and upper arms
• Note: Reconstituted DSIP degrades faster than most peptides; use within 2 weeks

Common Discussion Topics

1. Sleep quality optimization — DSIP is discussed as a peptide approach to improving sleep architecture, particularly delta (slow-wave) sleep, without the sedative or dependency profiles of pharmacological sleep aids
2. Stress resilience — Its HPA axis modulation properties generate interest in stress management and adrenal support contexts
3. Recovery and performance — Enhanced slow-wave sleep is associated with growth hormone release and physical recovery, linking DSIP to athletic recovery discussions
4. Withdrawal support — Historical clinical data on alcohol and opioid withdrawal generates discussion, though these studies were small and require replication
5. Stability challenges — DSIP's short half-life and reconstituted solution instability are practical concerns frequently discussed in research contexts
6. Stacking considerations — Discussions of DSIP in combination with other sleep-supportive compounds and peptides

Limitations of Current Research

1. Receptor unidentified — Despite decades of research, no specific receptor for DSIP has been definitively characterized
2. Aging clinical data — Most human studies were conducted in the 1980s with small sample sizes and limited controls by modern standards
3. Reproducibility concerns — Some early somnogenic findings proved difficult to reproduce across laboratories
4. Stability issues — Rapid degradation complicates both research protocols and practical use
5. Limited modern clinical investigation — No large-scale, randomized controlled trials have been conducted

Related Compounds

• Humanin — a mitochondrial-derived peptide with neuroprotective properties
• MOTS-c — a mitochondrial-derived peptide involved in metabolic regulation
• Epitalon — a tetrapeptide studied for circadian rhythm regulation and geroprotective effects
• GHRP-6/GHRP-2 — growth hormone secretagogues that also influence sleep architecture
• Selank — a synthetic peptide with anxiolytic properties sometimes discussed alongside DSIP for stress and sleep optimization applications